万孚生物(300482) - 2018 Q3 - 季度财报

Financial Performance - Operating revenue for the period was CNY 352,466,668.49, a year-on-year increase of 14.39%[9] - Net profit attributable to shareholders was CNY 60,371,507.41, representing a 37.71% increase year-on-year[9] - Net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 57,127,949.03, up 40.81% year-on-year[9] - Basic earnings per share increased by 35.71% to CNY 0.19[9] - The weighted average return on net assets was 3.19%, an increase of 4.54 percentage points compared to the previous year[9] - Total operating revenue for Q3 2018 reached CNY 352.47 million, an increase of 14.36% compared to CNY 308.12 million in the same period last year[35] - Net profit attributable to the parent company was CNY 43.84 million, compared to CNY 47.83 million in the previous year, reflecting a decrease of 8.36%[37] - The net profit for the third quarter reached CNY 39,899,101.12, compared to CNY 26,926,720.72 in the same period last year, representing a growth of approximately 48%[41] - The total profit for the current period was ¥206,596,527.88, up from ¥150,960,682.52, marking a growth of 36.9%[49] Asset and Equity Growth - Total assets increased by 48.82% to CNY 2,522,223,498.05 compared to the end of the previous year[9] - Net assets attributable to shareholders increased by 80.61% to CNY 1,858,479,288.82 compared to the end of the previous year[9] - The company's equity attributable to shareholders reached CNY 1.86 billion, a significant increase from CNY 1.03 billion, marking a growth of 80.36%[34] - The company's total assets increased to CNY 2.07 billion, up from CNY 1.29 billion at the beginning of the year, representing a growth of 60.93%[33] Cash Flow and Liquidity - Cash flow from operating activities for the year-to-date was CNY 53,511,061.05, a significant increase of 124.09%[9] - Cash and cash equivalents decreased by 36% to ¥303,691,743.76 from ¥473,003,092.99 due to increased investment funds[20] - The company’s cash and cash equivalents at the end of the period were ¥229,094,546.61, down from ¥306,151,823.15 in the previous period[53] - The net increase in cash and cash equivalents was CNY -102,205,960.13, reflecting a decline of CNY 324,855,198.80 from the previous period[56] Investment and Expenses - Research and development expenses for the quarter were CNY 31.35 million, up 27.45% from CNY 24.57 million year-on-year[35] - Research and development expenses increased to ¥69,860,283.81, up from ¥54,025,945.18, reflecting a growth of 29.2%[48] - The company reported a financial expense of CNY -8.37 million, a significant improvement compared to CNY 4.76 million in the previous year[35] Shareholder Information - The company had a total of 11,884 shareholders at the end of the reporting period[13] - The top ten shareholders held a combined 38.84% of the company's total shares[14] - The company executed a profit distribution plan, distributing ¥5 per share and increasing capital by 80% through stock conversion[22] Current Liabilities and Receivables - Accounts receivable decreased by 41% to ¥645,000 from ¥1,091,916.96, attributed to a reduction in subsidiary receivables[20] - Total current liabilities increased, with accounts payable rising to ¥144,405,417.78 from ¥140,483,862.70[29] Market Strategy - The company plans to continue expanding its market presence and investing in new product development to drive future growth[41]